Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Initial IND Warnings For CBD Supplements Could Ignite Regulatory Test

This article was originally published in The Tan Sheet

Executive Summary

FDA's warnings that supplements containing cannabis-derived ingredients are adulterated comes 10 months year after it stated the policy and a year after submitting other warnings that stopped short of saying the ingredients are noncompliant.

You may also be interested in...



Cannabidiol Patch With 14-Hour Delivery OK In UK, But Not Pain, Anxiety And Diabetes Claims

UK advertising regulator says an ad catalog retailer claiming a CBD patch could reduce chronic pain, anxiety and diabetes violated advertising codes. The agency says claims including the product penetrated quickly through skin were medicinal and not approved by the UK or EU.

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

It's Complicated: FDA Prohibits CBD In Supplements, Enforcement Priority On Disease Claims

As FDA announces its first-ever approval of a drug that contains a substance derived from marijuana, officials say the agency's policy that prohibits CBD's use in dietary supplements or food will not change. They also say, however, that FDA's priority for enforcement actions against dietary supplements containing CBD, an extract from cannabis and hemp plants, will remain on products marketed with drug or disease claims.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS108166

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel